Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MYL

Mylan (MYL) Stock Price, News & Analysis

Mylan logo

About Mylan Stock (NASDAQ:MYL)

Advanced Chart

Key Stats

Today's Range
$15.86
$15.86
50-Day Range
$14.37
$15.86
52-Week Range
$12.75
$23.11
Volume
4,016 shs
Average Volume
6.49 million shs
Market Capitalization
$8.59 billion
P/E Ratio
29.92
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Receive MYL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mylan and its competitors with MarketBeat's FREE daily newsletter.

MYL Stock News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
Dog competition comes to Mylan Park
See More Headlines

MYL Stock Analysis - Frequently Asked Questions

Mylan (NASDAQ:MYL) released its quarterly earnings data on Friday, November, 6th. The company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.16 by $0.15. Mylan's revenue for the quarter was up .4% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mylan investors own include Bristol-Myers Squibb (BMY), Meta Platforms (META), NVIDIA (NVDA), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Netflix (NFLX) and Micron Technology (MU).

Company Calendar

Last Earnings
11/06/2020
Today
5/27/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MYL
Fax
N/A
Employees
35,000
Year Founded
N/A

Profitability

Trailing P/E Ratio
29.92
Forward P/E Ratio
3.55
P/E Growth
2.01
Net Income
$16.80 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.50 billion
Cash Flow
$8.76 per share
Price / Cash Flow
1.81
Book Value
$23.02 per share
Price / Book
0.69

Miscellaneous

Free Float
N/A
Market Cap
$8.59 billion
Optionable
Optionable
Beta
1.45
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:MYL) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners